01 August 2022

Professionals from the Pharmacy Service and the Information Systems of the Bellvitge University Hospital (HUB) have just been awarded in the latest edition of the "Laboratorio de Ideas FarmaImpulso"


The scientific committee has decided to award the second prize to the HUB for the best innovative project in hospital pharmacy

29 July 2022

Hospital de Bellvitge and IDIBELL are studying the efficacy of Efavirenz, an antiretroviral against HIV, for the treatment of Niemann Pick type C in a clinical trial.

The good results of the drug in mice give hope that Efavirenz can alleviate cognitive impairment and learning and behavior problems.

The Niemann Pick Spain Foundation, based in Lleida, financed the assay.

Researchers are interested in replicating the study design in the international arena

26 July 2022

The Spanish Society of Cardiology (SEC) has awarded the SEC-Excellent certificate to the Familial Heart Diseases Unit of the Bellvitge University Hospital (HUB) for the treatment of genetic cardiovascular diseases. This unit is closely linked to the BIOHEART research group in Cardiovascular Diseases of IDIBELL.

25 July 2022

"Phew! How shameful, if it doesn’t light up... And, what if my legs fail me on the way...? This is how the publication "Bellvitge Informatiu" described what was going through Montserrat Fernández's mind as she carried the Olympic torch on behalf of Bellvitge Hospital.

There were quite a few professionals from the HUB, who volunteered for the Barcelona'92 Olympic Games, such a rewarding experience.

21 July 2022

The heart was extracted at the Germans Trias i Pujol Hospital and the transplant was then performed at the HUB, completing a highly complex procedure.

So far this year, three heart transplants in controlled asystole have been performed at the HUB.

20 July 2022
29 reference centres in the United States, Canada, the Netherlands, Italy, France and Spain, including Bellvitge University Hospital (HUB), have participated in an international multicentre study that has validated a model for risk prediction of ventricular arrhythmias and sudden death in arrhythmogenic right ventricular cardiomyopathy (ARVC). This calculator can be used as a guide for relevant clinical decision making and is freely available at ARVCrisk.com.